These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36503114)

  • 1. Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial.
    Okinaka K; Akeda Y; Inamoto Y; Fuji S; Ito A; Tanaka T; Kurosawa S; Kim SW; Tanosaki R; Yamashita T; Ohwada C; Kurata K; Mori T; Onozawa M; Takano K; Yokoyama H; Koh K; Nagafuji K; Nakayama K; Sakura T; Takahashi T; Oishi K; Fukuda T
    Clin Microbiol Infect; 2023 Apr; 29(4):482-489. PubMed ID: 36503114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
    Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Azuma M; Oishi K; Akeda Y; Morino S; Motoki Y; Hanibuchi M; Nishioka Y
    Vaccine; 2023 Jan; 41(5):1042-1049. PubMed ID: 36593171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation.
    Garcia Garrido HM; Haggenburg S; Schoordijk MCE; Meijer E; Tanck MWT; Hazenberg MD; Rutten CE; de Bree GJ; Nur E; Meek B; Grobusch MP; Goorhuis A
    Am J Hematol; 2022 May; 97(5):592-602. PubMed ID: 35147238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
    Rezende RPV; Oliveira-Santos M; Andrade LEC; Klumb EM
    Lupus; 2023 Apr; 32(5):694-703. PubMed ID: 36705619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
    Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
    Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
    Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
    Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
    Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
    Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
    Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Reddy KR; Abarca K; Khaertynova IM; Dagan R; Dawson R; McCauley J; Shekar T; Fu W; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2177066. PubMed ID: 36864601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.